Premium
The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy‐Progress and Novel Therapeutic Opportunities
Author(s) -
Mohamed Iman A.,
Krishnamoorthy Navaneethakrishnan T.,
Nasrallah Gheyath K.,
Da'as Sahar I.
Publication year - 2017
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.25639
Subject(s) - hypertrophic cardiomyopathy , gene , phenotype , biology , mutation , myosin , genetics , genetic heterogeneity , microbiology and biotechnology , biochemistry
Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene encodes the cardiac myosin‐binding protein C, cMYBPC3 is amongst the various sarcomeric genes that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP‐C proteins. In this review, we will discuss the implications and molecular mechanisms involved in MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed into potential therapeutics for the treatment of HMC. J. Cell. Physiol. 232: 1650–1659, 2017. © 2016 Wiley Periodicals, Inc.